Ann: Cynata announces CEO succession and Board changes, page-44

We're off topic pledge. The news in this thread is pretty substantial in its own right.

I think Kilian will need to make one heck of a speach or statement (in an announcement or report) at some point to show a) they his appointment is not a mistake and b) that he can articulate a vision and explain how he (as opposed to how Ross) sees CYP's value proposition.

To me Kilian comes in with some baggage - he was the science guy, to my mind, who was responsible for the design of the MEND trial. To my mind he failed to set up a trial that was big enough (statistically powered enough) to cater for ARDS treatments being different across hospitals. And in my opinion his poor design never came to light in part because the trial was not finished.

Jolanta gets a complete pass from me for inheriting MEND - she isn't to blame for its design flaws. But has Kilian ever run a successful trial? Ever designed one? I don't know what he did at Mesoblast when he was there - do you?